Ming Li

Publications (3)9.12 Total impact

• Article: Statins and the risk of lung cancer: a meta-analysis.

  Min Tan, Xiaolian Song, Guoliang Zhang, Aimei Peng, Xuan Li, Ming Li, Yang Liu, Changhui Wang
  [show abstract] [hide abstract]
  ABSTRACT: Several epidemiologic studies have evaluated the association between statins and lung cancer risk, whereas randomized controlled trials (RCTs) on cardiovascular outcomes provide relevant data as a secondary end point. We conducted a meta-analysis of all relevant studies to examine this association. A systematic literature search up to March 2012 was performed in PubMed database. Study-specific risk estimates were pooled using a random-effects model. Nineteen studies (5 RCTs and 14 observational studies) involving 38,013 lung cancer cases contributed to the analysis. They were grouped on the basis of study design, and separate meta-analyses were conducted. There was no evidence of an association between statin use and risk of lung cancer either among RCTs (relative risk [RR] 0.91, 95% confidence interval [CI] 0.76-1.09), among cohort studies (RR 0.94, 95% CI 0.82-1.07), or among case-control studies (RR 0.82, 95% CI 0.57-1.16). Low evidence of publication bias was found. However, statistically significant heterogeneity was found among cohort studies and among case-control studies. After excluding the studies contributing most to the heterogeneity, summary estimates were essentially unchanged. The results of our meta-analysis suggest that there is no association between statin use and the risk of lung cancer.
  PLoS ONE 01/2013; 8(2):e57349. · 4.09 Impact Factor
• Article: Bronchial Fibroepithelial Polyp: A Case Report and Review of the Literature.

  Ming Li, Guoliang Zhang, Aimei Peng, Changhui Wang
  [show abstract] [hide abstract]
  ABSTRACT: Fibroepithelial polyps of the bronchus are uncommon. We herein report a rare case of a recurrent bronchial fibroepithelial polyp. A 61-year-old man was admitted to the hospital due to recurrent pneumonia. Chest computed tomography showed consolidation and atelectasis in the right lower lobe. Bronchoscopy revealed a mobile polypoid tumor protruding from the right lower lobe bronchus. We performed endobronchial resection, and a pathological examination revealed a fibroepithelial polyp. However, surveillance bronchoscopy performed six months after tumor resection detected a relapse. We herein report a case of a recurrent bronchial fibroepithelial polyp and also review the relevant literature.
  Internal Medicine 01/2013; 52(3):373-376. · 0.94 Impact Factor
• Source

  Available from: PubMed Central

  Article: Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.

  Ming Li, Qian Zhang, Peifang Fu, Ping Li, Aimei Peng, Guoliang Zhang, Xiaolian Song, Min Tan, Xuan Li, Yang Liu, Yueping Wu, Suyun Fan, Changhui Wang
  [show abstract] [hide abstract]
  ABSTRACT: To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with previously untreated advanced non-small cell lung cancer (NSCLC). Methods: A meta-analysis was performed using trials identified through PubMed, EMBASE, and Cochrane databases. Two investigators independently assessed the quality of the trials and extracted data. The outcomes included overall survival (OS), progression-free survival (PFS), response rate (RR), and different types of toxicity. Hazard ratios (HRs), odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled using RevMan software. Results: Four trials involving 2,518 patients with previously untreated advanced NSCLC met the inclusion criteria. Pemetrexed plus platinum chemotherapy (PPC) improved survival compared with other platinum-based regimens (PBR) in patients with advanced NSCLC (HR = 0.91, 95% CI: 0.83-1.00, p = 0.04), especially in those with non-squamous histology (HR = 0.87, 95% CI: 0.77-0.98, p = 0.02). No statistically significant improvement in either PFS or RR was found in PPC group as compared with PBR group (HR = 1.03, 95% CI: 0.94-1.13, p = 0.57; OR = 1.15, 95% CI: 0.95-1.39, p = 0.15, respectively). Compared with PBR, PPC led to less grade 3-4 neutropenia and leukopenia but more grade 3-4 nausea. However, hematological toxicity analysis revealed significant heterogeneities. CONCLUSION: Our results suggest that PPC in the first-line setting leads to a significant survival advantage with acceptable toxicities for advanced NSCLC patients, especially those with non-squamous histology, as compared with other PRB. PPC could be considered as the first-line treatment option for advanced NSCLC patients, especially those with non-squamous histology.
  PLoS ONE 01/2012; 7(5):e37229. · 4.09 Impact Factor